News

At MDS 2025, the professor of neurology at University de Tunis El Manar described the role of global collaboration in advancing the understanding, diagnosis, and management of Parkinson disease. [WATCH TIME: 6 minutes]

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

The research portfolio director at the Muscular Dystrophy Association spoke about ongoing advances in ALS research and how they may inform approaches to therapeutic development. [WATCH TIME: 5 minutes]

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

A phase 2 trial shows NNZ-2591 improves symptoms in children with Phelan-McDermid syndrome, paving the way for a phase 3 study.

Oculis advances Privosegtor, a potential first neuroprotective therapy for optic neuritis, following FDA breakthrough designation and promising trial results.

The clinical assistant professor at Feinberg School of Medicine outlined some of the major revisions proposed for the NMOSD diagnostic criteria presented at ECTRIMS 2025. [WATCH TIME: 8 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy comorbidities!

Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, provided an outlook on the 2026 MDA meeting and what clinicians should look forward to in preparation.

Neurology News Network for the week ending January 10, 2025. [WATCH TIME: 4 minutes]

A review of clinical trial and real-world data found no evidence that oral anticoagulants increase brain imaging abnormalities in patients treated with lecanemab or donanemab for early Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 9, 2026.

Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology.

Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Johannes Streffer, MD. [LISTEN TIME: 14 minutes]

In a pilot study, liraglutide, a drug used for diabetes and weight-loss, significantly reduced headache days in patients with obesity and chronic or high-frequency migraine, suggesting a potential new preventive therapy.

At ECTRIMS 2025, the professor of biomedical engineering at the University of Bern discussed virtual reality technologies for multiple sclerosis rehabilitation. [WATCH TIME: 3 minutes]

A recent analysis reveals fenfluramine's positive effects on executive functioning in adults with Lennox-Gastaut syndrome, independent of seizure reduction.

The director of the EEG/Epilepsy Unit in the Department of Clinical Neurosciences at Lausanne University Hospital in Switzerland discussed post-anoxic seizure management at 2025 AES Annual Meeting. [WATCH TIME: 3 minutes]

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic shared data from the phase 2 CALIPER trial of vidofludimus calcium in progressive MS presented at ECTRIMS 2025. [WATCH TIME: 7 minutes]

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Fenfluramine shows significant seizure reduction in CDKL5 deficiency disorder, offering hope for families facing treatment-resistant epilepsy challenges.

A pair of pediatric epileptologists highlight the systemic and patient level factors driving inequities in infantile epileptic spasms syndrome care and outline paths toward more equitable diagnosis and treatment.

Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.

An AES study revealed the real-world persistence of fenfluramine in treating Lennox-Gastaut syndrome, highlighting patient demographics and treatment trends.

A neurologist at St Vincent's Hospital shared recently presented findings from a phase 2 study of tazbentetol, a novel synaptogenic small molecule, in mild-to-moderate Alzheimer disease. [WATCH TIME: 4 minutes]